Alberto Borghetti

14PUBLICATIONS
31CO-AUTHORS
PharmacogenomicsGene and molecular therapyBehavioural epidemiologyEpidemiological methodsPoverty, inclusivity and wellbeing
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 15, 2026
'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort.

|Jan 28, 2026
The Role of Prior HBV Infection on the Efficacy of 3TC/DTG as a Maintenance Therapy.

Tommaso Matucci, Sara Occhineri, Alessandra Palomba

|Oct 31, 2024
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort.

Arturo Ciccullo, Gianmaria Baldin, Adriana Cervo

|Oct 06, 2024
Efficacy and Tollerability of INI-Based 2-Drug Regimen in Virosuppressed Persons Living with HIV: A Systematic Review and Meta-Analysis.

Antonio Russo, Salvatore Martini, Mariantonietta Pisaturo

|Apr 29, 2024
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed.

Alberto Borghetti, Arturo Ciccullo, Francesca Lombardi

|Feb 25, 2023
Reduced probability of improving viro-immunological state in subjects with vertical transmission of HIV reaching adult age: A multicenter retrospective cohort study.

Francesca Pennati, Stefano Calza, Antonio Di Biagio

Pageof 3

Frequent Collaborators

11 joint publications

Arturo Ciccullo

6 joint publications

Gianmaria Baldin

3 joint publications

Simone Belmonti

3 joint publications

Massimiliano Fabbiani